ISO Factory Supply Tirzepatide Gip\GLP-1 CAS 2023788-19-2 for Weight Loss

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: TGYBIO2023110801
• Product Name: Tirzepatide
• Appearance: White Powder
• Test Methods: HPLC
• Shelf Life: 2 Years
• Shipping Methods: DHL, FedEx, TNT and EMS
• MOQ: 10mg
• CAS No.: 2023788-19-2
• Capsules: Available
• Sample: Available
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• Production Capacity: 5000g

Product Description

Product name	tirzepatide
Other name	Tirzepatide;GIP\GLP-1;Tirzepatide (LY3298176);Trizepatide;Gip\GLP-1 Tirzepatide Ly3298176 Peptide;Tilposide;Tirzepatide(GLP-1);terzapitide
CAS NO	1078-21-3
Molecular  formula	/
Molecular  weight	/
Assay	99%
Appearance	White Powder
Usage	Tirzepatide can be used as a single therapy (on its own) or with other diabetes medicines, including sulfonylureas, SGLT2 inhibitors or metformin.

_{Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence has PEG modification, which is the functional group of the polypeptide, and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is glucose-dependent  nutrition polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor double agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.}


 

• Tirzepatide has been shown to help lose weight in overweight patients. Phase 3 clinical trials are currently underway for weight loss in adults who are overweight, obese, or have weight-related health issues. Tirzepatide has received FDA  Fast Track designation to speed up its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions. 
• In the SURMOUNT-1 clinical trial, the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

_{tirzepatide is a once-weekly glucose-dependent-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by scientists. ChemicalbookGIP and GLP-1 are both hormones secreted by the gut that promote secretion. tirzepatide combines the effects of two -promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.}